Abstract Purpose: Preferentially expressed antigen on melanomas (PRAME) is an interesting antigen for T-cell therapy because it is frequently expressed in melanomas (95%) and other tumor types. Moreover, due to its role in oncogenic transformation, PRAME-negative tumor cells are not expected to easily arise and escape fromT-cell immunity. The purpose of this study is to investigate the usefulness of PRAME as target for anticancerT-cell therapies. Experimental Design: HLA-A*0201-subtyped healthy individuals and advanced melanoma patients were screened for CD8 + T cells directed against previously identified HLA-A*0201-binding PRAME peptides by IFN-g enzyme-linked immunosorbent spot assays and tetramer staining. PRAME-specificT-cell clones were isolated and tested for recognition of melanoma and acute lymphoid leukemia (ALL) cell lines. PRAME mRNA expression was determined by quantitative real-time reverse transcription-PCR. Results: In 30% to 40% of healthy individuals and patients, PRA 100-108 -specific CD8 + T cells were detected both after in vitro stimulation and directly ex vivo after isolation by magnetic microbeads. Although CD45RA À memory PRA 100-108 -specific T cells were found in some individuals, the majority of PRA 100-108 -tetramer + Tcells expressed CD45RA, suggesting a naive phenotype. PRA 100-108 -tetramer + T-cell clones were shown to recognize and lyse HLA-A*0201 + and PRAME + melanoma but not ALL cell lines. Quantitative real-time reverse transcription-PCR showed significantly lower PRAME mRNA levels in ALL than in melanoma cell lines, suggesting that PRAME expression in ALL is below the recognition threshold of our PRA 100-108 -tetramer + Tcells. Conclusion: These data support the usefulness of PRAME and in particular the PRA [100][101][102][103][104][105][106][107][108] epitope as target forT-cell therapy of PRAME-overexpressing cancers.
Tumor antigens that are used as targets in clinical studies belong to the melanocyte differentiation antigens, cancer-testis antigens, or antigens overexpressed in tumors (1 -5) . Cancertestis antigens are expressed in different tumors but not in normal tissues, except for testis, and are therefore useful targets for T-cell therapy. Most cancer-testis antigens, however, are expressed at low frequencies (30-50%).
Preferentially expressed antigen on melanomas (PRAME) has been identified as an antigen recognized by an HLA-A24-restricted CTL isolated from a melanoma patient (6) . Semiquantitative reverse transcription-PCR (RT-PCR) analysis showed frequent PRAME expression in melanomas (95%) and other tumor types, including lung and breast tumors and leukemias but not in healthy tissues, except for testis and low expression in endometrium, ovaries, and adrenals. DNA microarray analysis revealed the gene encoding PRAME as one of the genes of an expression profile for poor prognosis in breast carcinoma (7) . Recently, the function of PRAME has been elucidated by Epping et al. (8) . PRAME binds to retinoic acid receptor a, thereby inhibiting retinoic acid -induced differentiation, growth arrest, and apoptosis. Suppression of high levels of endogenous PRAME in retinoic acid -resistant melanoma cells by RNA interference restores sensitivity to the antiproliferative effects of retinoic acid, suggesting that PRAME overexpression contributes to oncogenesis by inhibiting retinoic acid signaling.
In this study, HLA-A*0201-subtyped healthy individuals and advanced melanoma patients were screened for T cells directed against four previously identified HLA-A*0201-binding PRAME epitopes (9) by IFN-g enzyme-linked immunosorbent spot (ELISPOT) assays and tetramer staining. T cells specific for PRA [100] [101] [102] [103] [104] [105] [106] [107] [108] were most frequently found both after in vitro stimulation and directly ex vivo after isolation by magnetic microbeads. Furthermore, PRA 100-108 -tetramer + T-cell clones were isolated and shown to recognize and lyse tumor cells expressing high levels of PRAME, supporting the usefulness of PRAME as target for immunotherapy.
Materials and Methods
Cell lines and culture conditions. Melanoma cell lines 453A0, 513D, 518A2, and IGR39D were established in our laboratory. Cell lines FM6 and FM3 were kindly provided by J. Zeuthen (Copenhagen, Denmark). Breast carcinoma cell line MDA-231 was obtained from the American Type Culture Collection (Manassas, VA). All cell lines were cultured in DMEM (Invitrogen, Breda, the Netherlands) supplemented with 8% FCS, 4 mmol/L L-glutamine, 50 Ag/mL penicillin, and 50 Ag/mL streptomycin. The Leiden acute lymphoid leukemia (
, and L-CML-B were cultured as described (10) . L-CML-B is derived from a patient with lymphoblastic crisis of chronic myeloid leukemia (CML) but has phenotypic characteristics of ALL. K562-A2 and K562-A3 are generated by transduction of cell line K562 with retroviral vectors encoding HLA-A*0201 and A*0301. K562-A2, K562-A3 and EBV-B cell lines were cultured in RPMI with penicillin/ streptomycin and 8% FCS. The T2 cell line was cultured in Iscove's modified Dulbecco's medium (IMDM) with penicillin/streptomycin and 5% FCS.
In vitro stimulation of peripheral blood mononuclear cells. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood from healthy individuals and melanoma patients (American Joint Cancer Committee stages III and IV) by Ficoll gradient centrifugation. The study was approved by the local Medical Ethical Committee, and informed written consent was given by all individuals. Individuals were subtyped as HLA-A*0201 by PCR. PBMCs were seeded at 3 Â 10 6 per well in 24-well plates in T-cell medium [IMDM with penicillin/streptomycin; 116 Ag/mL L-arginine, 36 Ag/mL L-asparagine, and 215 Ag/mL L-glutamine; 10% human serum; and 150 IU/mL human recombinant interleukin-2 (IL-2)], containing 2 Ag/mL of PRAME (PRA 100-108 , PRA 142-151 , PRA 300-309 , and PRA 425-433 ) or influenza (FLU [58] [59] [60] [61] [62] [63] [64] [65] [66] ) peptides (9, 11) . At day 11, PBMCs were collected, washed, and seeded at 3 Â 10 6 per well in 24-well plates in T-cell medium without peptides. At day 13, PBMCs were tested for specific CD8 + T cells by IFN-g ELISPOT assays and tetramer staining. IFN-g ELISPOT assay. The IFN-g ELISPOT assay was done as described (12) ) and all PBMCs after isolation were stained with anti-CD8-FITC and anti-CD45RA-APC in PBA for 30 minutes at 4jC. After washing, cells were analyzed by fluorescence-activated cell sorting. PI was added (5 Ag/mL) to exclude dead cells.
Generation and isolation of PRA 100-108 -specific CD8 + T cells. Adhererent monocytes from HD13 were cultured in AIM-V (Invitrogen, Breda, the Netherlands) with L-arginine/L-asparagine/L-glutamine and penicillin/streptomycin supplemented with 500 units/mL IL-4 (Peprotech, Inc., Rocky Hill, NJ) and 800 units/mL granulocyte macrophage colony-stimulating factor (Behringwerke, Marburg, Germany) for 8 days. Dendritic cells were pulsed with 10 Ag/mL PRA 100-108 peptide in IMDM with penicillin/streptomycin for 4 hours, washed, and subsequently incubated with autologous nonadherent PBMCs in IMDM with penicillin/streptomycin, L-arginine/L-asparagine/L-glutamine, 10% human serum, 10 ng/mL IL-7 (Peprotech), and 100 pg/mL IL-12 (Sigma-Aldrich, Zwijndrecht, the Netherlands). T-cell cultures were weekly restimulated with autologous dendritic cells pulsed with PRA 100-108 as described above in T-cell medium. At day 21, PRA Quantitative real-time RT-PCR. Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA). Random-primed cDNA was synthesized according to manufacturer's instructions (Roche, Indianapolis, IN). The PRAME 5 ¶-TCACTTGTTGCCACGCACGTCTGA-3 ¶ and housekeeping porphobilogen deaminase (PBGD) 5 ¶-CTCATCTTTGGGCTGTT-TTCTTCCGCC-3 ¶ probes were designed using Primer Express software (Applied Biosystems, Foster City, CA) and labeled with reporter dye TET at the 5 ¶ end and quencher dye TAMRA at 3 ¶ end (Eurogentec, Seraing, Belgium). The forward PRAME primer 5 ¶-GTCAACAGCAACTTCGCGGT-3 ¶ was selected on the junction of exons 1 and 2 at position 94 bp (GeneID 23532), and the reverse PRAME primer 5 ¶-AATGGAACCCCA-CAAACGC-3 ¶ was selected on the junction of exons 3 and 4 at position 265 bp. The forward and reverse primers for PBGD (GeneID 3145) are 5 ¶-GGCAATGCGGCTGCAA-3 ¶ and 5 ¶-GGGTACCCACGCGAATCAC-3 ¶, respectively. PCR was done using the qPCR core kit (Eurogentec). Amplification was started with 10 minutes at 95jC followed by 55 cycles of 15 seconds at 95jC, 30 seconds at 65jC, and 30 seconds at 65jC. The 171-bp PRAME product was confirmed by DNA sequencing. PRAME expression was normalized to expression of the PBGD gene.
Results
In vitro expansion of PRAME-specific CD8 + T cells. To investigate whether human individuals have circulating T cells specific for PRAME, total PBMCs from HLA-A*0201-subtyped healthy individuals and melanoma patients were stimulated in vitro with four previously identified HLA-A*0201-binding PRAME peptides (9) and tested for PRAME-specific T cells by IFN-g ELISPOT assays and tetramer staining.
Of the four PRAME peptides, T cells specific for PRA [100] [101] [102] [103] [104] [105] [106] [107] [108] were most frequently found by ELISPOT and tetramer staining ( Fig. 1; -specific T-cell clones were isolated, and four clones (clones 3, 7, 33, and 34) were tested for specific cytokine release by Cytometric Bead Array. All clones expressed CD8, CD45RO, and TCRVh7.1 but not CD27, CD28, and CCR7 (data not shown). Figure 4A shows that PRA 100-108 -tetramer + T-cell clones released significant levels of IL-4, IL-5, and IFN-g and low + T cells from HD14 tested immediately after isolation from peptide-stimulated PBMCs (data not shown). However, all T cells isolated from peptide-stimulated PBMCs, as shown in Fig. 1 , failed to expand to sufficient numbers for detailed analysis.
The avidities of the PRA 100-108 -tetramer + T cell clones were determined by titrating the PRA 100-108 peptide on HLA-A*0201 + T2 cells (Fig. 4B) . Specific cytokine release could be measured at 1 ng/mL of PRA 100-108 peptide. Moreover, at suboptimal peptide concentrations, PRA 100-108 -specific T cell clones released more IL-4 and IL-5 than IFN-g. with PRA 100-108 -tetramer + T cells (Fig. 4D ) and increased uptake of PI (data not shown).
PRAME mRNA expression by quantitative real-time RT-PCR. Total mRNA was isolated from melanoma and ALL cell lines to investigate PRAME expression levels by quantitative real-time RT-PCR (data not shown). All melanoma cell lines expressed high levels of PRAME mRNA (f10-fold lower than in K562). PRAME mRNA levels in ALL cell lines, however, were significantly lower (f100-to 1,000-fold) than in melanoma cell lines.
Discussion
The human PRAME protein is frequently expressed in tumors of various histologic origins. In this report, we investigated the usefulness of PRAME as target for anticancer T-cell therapy. HLA-A*0201-subtyped healthy individuals and advanced melanoma patients were screened for CD8 + T cells directed against four previously identified PRAME epitopes (9) . The results show that T cells specific for PRA 100-108 are most frequently found in 30% to 40% of healthy individuals and melanoma patients after in vitro stimulation. PRA 100-108 -tetramer + T cells could not be detected directly ex vivo before isolation by magnetic microbeads due to the low frequency of these T cells in peripheral blood (f4 to 40 antigenspecific T cells in 1 Â 10 6 CD8 + cells). After isolation by magnetic microbeads, however, PRA 100-108 -tetramer + T cells were found in the same individuals as after in vitro stimulation, showing that magnetic microbeads allow rapid ex vivo isolation and phenotyping of low-frequency tetramer + T cells.
Variable numbers of memory (CD45RA À ) PRA 100-108 -tetramer + T cells were found in two healthy individuals and one melanoma patient. The majority of PRA 100-108 -tetramer + T cells, however, expressed CD45RA, suggesting a naive phenotype. The presence of naive PRA 100-108 -tetramer + T cells in melanoma patients indicates that these T cells have not been activated in vivo by PRAME-expressing tumor cells possibly due to lack of danger signals, defective dendritic cell function, or production of immunosuppressive factors (13 -15) . The presence of memory PRA 100-108 -tetramer + T cells in a minority of individuals remains unclear. These T cells might have been activated in vivo by PRAME-expressing benign or malignant cells or by foreign antigen mimicry, as shown for the MART-1/Melan-A 27-35 peptide (16) . Natural T-cell immunity against tumor cells seems to occur frequently (17) , but the tumor antigens recognized are often unknown. MART-1/Melan-A-tetramer + T cells are readily detectable directly ex vivo in melanoma patients and healthy individuals due to the high frequency of these T cells in peripheral blood (f400 to 4,000 antigen-specific T cells in 1 Â 10 6 CD8 + cells). These MART-1/Melan-A-specific T cells have been shown to display a memory or naive phenotype (18, 19) . It has been suggested that MART-1/Melan-A-specific T cells with a memory phenotype are induced in vivo upon tumor progression due to the presence of high antigen load (20) . At that stage, the antigen-specific T cells apparently fail to counter tumor progression; therefore, therapies boosting naturally acquired antitumor responses are not expected to be very effective. Because circulating PRA 100-108 -specific T cells display a naive phenotype in most patients, in vivo immunization with peptides covering the PRA 100-108 epitope may be an effective strategy to stimulate antitumor T-cell reactivity.
To investigate whether PRA 100-108 -tetramer + T cells are able to recognize and lyse tumor cells, PRA 100-108 -specific T cells were induced in vitro by stimulating PBMCs from HD13 with peptide-pulsed dendritic cells. All T-cell clones released type 1 (IFN-g) and type 2 (IL-4 and IL-5) cytokines. This mixed Tc1/Tc2 cytokine pattern may be associated with the naive phenotype of these T cells in nonstimulated PBMCs from HD13, because PRA 100-108 -specific T cells from HD14, displaying a memory phenotype in nonstimulated PBMCs, were shown to have a more Tc1 cytokine profile, predominantly releasing IFN-g and tumor necrosis factor-a (data not shown).
All PRA 100-108 -specific T-cell clones recognized HLA-A*0201 + and PRAME + melanoma but not ALL cell lines. Quantitative real-time RT-PCR showed significantly lower (f100-to 1,000-fold) PRAME mRNA levels in ALL than in melanoma cell lines. These results do not support previous studies showing high levels of PRAME expression in ALL (21, 22) . A possible explanation for this discrepancy may be the use of different primer pairs in PCR reactions. A 171-bp PRAME fragment from positions 94 to 265 bp was amplified by our real-time RT-PCR, whereas others amplified a 560-bp fragment from positions 662 to 1,222 bp (21, 22) . Five PRAME mRNA variants have been described, all encoding the same PRAME protein. Two of these variants have an alternative exon 1 and may have been missed in our RT-PCR reactions due to partial homology to the forward primer. It can be speculated that high PRAME mRNA expression in ALL is caused by selective overexpression of these two PRAME variants. The differential recognition of melanoma and ALL cell lines by our PRA 100-108 -specific CD8 + T cell clones, however, makes this possibility unlikely and supports the finding that PRAME mRNA expression is significantly lower in ALL than in melanoma cell lines.
In standard 4-hour 51 Cr-release assays, we consistently observed low specific lysis of K562-A2 (10-20%) versus K562-A3 (0%) by PRA 100-108 -tetramer + T cells (data not shown), whereas these cells were lysed up to 80% after 2 days of coincubation. Similarly, with the exception of cell line 453A0, no specific lysis of melanoma cell lines could be measured in 51 Cr-release assays, whereas all HLA-A*0201 + and PRAME + melanoma cell lines were recognized in Cytometric Bead Array assays and killed after 2 days of coincubation with PRA 100-108 -tetramer + T cells. The slow killing mechanism might be attributed to release of low levels of granzyme B and perforin. Because the T-cell clones clearly recognise HLA-A*0201 + and PRAME + tumor cell lines in cytokine release assays, indicating that the affinity of the TCR is sufficiently high to recognize endogenously processed PRAME, transfer of the PRA 100-108 -specific TCR to CD8 + T cells with more powerful cytolytic machineries might be an effective strategy to generate potent tumor-specific T cells.
